Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects

Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects

The goal of this study is to evaluate the efficacy and safety of upadacitinib in adult and adolescent subjects with moderate to severe hidradenitis suppurativa (HS) who have failed anti-TNF therapy. The primary hypothesis is that upadacitinib will provide superior efficacy compared to placebo and will be well-tolerated in adult and adolescent subjects with HS. The study begins with a screening period to determine if subjects meet eligibility criteria. Those who are eligible will be randomized to receive daily oral dose of upadacitinib or matching placebo. Depending on their response, subjects may be re-randomized during later stages of the study.

Basic eligibility criteria:

Please contact the study coordinator for additional eligibility information.

Researchderm@arizona.edu

Inclusion criteria:
- subjects must be ≥ 12 years old.
- Diagnosed with HS by a dermatologist at least 6 months prior to study.
- Do not have other concomitant inflammatory skin disorders.
- Able to comprehend and read the English language.
- For subjects under 18, a parent/legal guardian will be asked to help read and interpret study content.

Primary disease category: Dermatology

Projected enrollment dates: April 2024

Official study title: Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects